More News! 23 Jun 2017 French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene therapy to restore sight in patients with the rare genetic disease Leber hereditary optic […] June 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 21 Jun 2017 Swedish IPO raises €51M for Biomaterials to Repair Bone Bonesupport has gone public in the Swedish stock market to push its pipeline and increase sales of biomaterials to regenerate bone tissue. Bonesupport is a company based in Lund, Sweden, that develops biomaterials to improve and speed up the repair of bones. The firm IPO’d today on the Nasdaq Stockholm, raising an impressive €51M with the participation […] June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017 Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […] June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 12 Jun 2017 Bacteria copy a Powerhouse in Plants to Produce Useful Molecules Danish researchers managed to sneak the genetic information needed to make P450 enzymes into E. coli. These enzymes are used by plants to make bioactive compounds and can be used for new industrial production processes of several drugs. Researchers from the Novo Nordisk Foundation Center for Biosustainability have been focusing on developing an alternative way to produce a plant enzyme, the cytochrome P450, for industrial […] June 12, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 10 Jun 2017 This Turkish Bioartist Creates Beautiful Maps out of Fungi Selin Balci uses fungi as a medium to create living maps that explore the complexity of microscopic life and its similarity with human behavior. Selin Balci got a degree in microbiology from Istanbul University and worked in research for 5 years before turning to art. Her work combines her experience culturing fungi and mold with creative experimentation to obtain colorful […] June 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 30 May 2017 FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […] May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Seed Funding for a German Cell Therapy to Prevent Transplant Rejection TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […] May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 19 May 2017 The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection Hansa Medical has accessed the EMA’s priority medicines scheme to accelerate the development of a therapy that broadens the access to kidney transplants. Hansa Medical, based in Lund, Sweden, develops enzymes with immunomodulatory properties. Its lead candidate, IdeS, has now been granted access to the EMA’s priority medicines (PRIME) scheme, designed to support the development […] May 19, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 18 May 2017 Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and based in Cambridge, has announced it made the last payment part of its acquisition deal with AxioMx. The deal was initiated in November 2015 with a […] May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 British Biotech Startup Partners with Takeda to Advance its T Cell Platform GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […] May 9, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 Scottish Shark Antibodies have caught Amgen’s Eye Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […] May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email